What Bellaseno does

BellaSeno GmbH is a clinical-stage medical device company headquartered in Leipzig, Germany, with an operational site in Brisbane/Burleigh Heads, Australia. The company develops a proprietary bioresorbable scaffold platform built on polycaprolactone (PCL) polymer, engineered with an interconnected porosity architecture to support vascularization and tissue ingrowth without biologics or stem cells. Manufacturing uses a proprietary high-speed additive manufacturing process (referred to as MagLev technology) intended to deliver reproducible quality and scalable production. Product candidates span a breast scaffold (lead focus for reconstruction, revision, and primary augmentation), chest wall/pectus scaffolds, bone regeneration scaffolds, and additional soft-tissue applications, all leveraging the shared PCL platform.

The company is pre-revenue with no commercial product on the market. Its business model centers on clinical development, regulatory approvals, and eventual global commercialization. Marketing channels include medical conferences, a LinkedIn presence, newsletter, earned media, and a dedicated clinical trial website (breastscaffoldtrial.com). Distribution is structured around an exclusive global licensing agreement with Mentor Worldwide LLC (Johnson & Johnson) for the breast scaffold platform, supplementing direct clinical-site engagement across multiple countries. Clinical experience spans 45+ patients across breast, pectus, and bone indications, with longest follow-up of up to six years, and a 19-patient BRV-004 cohort demonstrating 83% volume retention at two years.

Regulatory positioning is established: ISO 13485 certification, EU MDR 2017/745 compliance, and European market access (July 2023) for custom-made bone and pectus scaffolds; CE Mark for the breast scaffold is targeted for 2028 and FDA approval for 2030. Funding to date includes a Series A+B round (with Herbert Stadler as a disclosed investor and Chairman of the Supervisory Board) and a 2024 Australian government grant supporting a fully automated scaffold production facility in Australia.

Name

Bellaseno

Legal name

BellaSeno GmbH

Website

https://bellaseno.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

BellaSeno is a clinical-stage German medtech company developing a proprietary bioresorbable PCL scaffold platform for soft-tissue regeneration, currently focused on breast reconstruction and revision, with global commercialization via an exclusive licensing agreement with Mentor Worldwide LLC (Johnson & Johnson).

Ownership category

akta.pro rank

Product category

Resorbable Tissue Scaffolds

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)

akta.pro secondary industries

3D Bioprinting & Biofabrication (HLAAAGAC), Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH), 3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial) (HLAHAEAJ)

Keywords

• Bioresorbable tissue scaffolds
• Breast reconstruction devices
• Regenerative medicine
• Additive manufactured implants
• Soft tissue regeneration

Headquarters

HQ city

Leipzig

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Infrastructure, Marketing or Sales, Personnel

Revenue model

1. Medical Device Sales (Future): BellaSeno is a clinical-stage company currently focused on clinical development and regulatory approvals. The company is preparing for global market introduction of its breast scaffold platform. An exclusive global licensing agreement with Mentor Worldwide LLC (Johnson & Johnson) will support future commercialization through their established commercial infrastructure.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

BellaSeno designs, develops, and manufactures bioresorbable polycaprolactone (PCL) scaffolds that guide soft-tissue regeneration without biologics or stem cells. The scaffolds are produced via proprietary MagLev additive manufacturing and are offered in application-specific forms for breast reconstruction/revision/augmentation, chest wall and pectus excavatum correction, bone regeneration, and other soft-tissue indications. The company is clinical-stage and is preparing for global market introduction through its Mentor Worldwide LLC (Johnson & Johnson) licensing partnership.

Product overview

BellaSeno is a clinical-stage medtech company advancing a bioresorbable scaffold platform for soft-tissue restoration. The company offers a unified platform technology based on proprietary PCL (polycaprolactone) scaffolds with interconnected porosity. The platform is applied across multiple clinical indications: Breast Scaffold (primary focus for reconstruction, revision, and augmentation), Chest Wall/Pectus Scaffold, Bone Regeneration Scaffold, and Other Soft Tissue applications. The scaffolds are designed to guide the body's own tissue formation, providing temporary structure before gradually resorbing and leaving native tissue behind. All products share the core PCL scaffold platform with application-specific designs.

Differentiator

Problem solved

Functional benefit

Products and services

• Breast Scaffold Bioresorbable PCL scaffold designed to guide soft tissue formation for breast reconstruction, revision, and primary augmentation procedures. Provides temporary structure supporting fat graft integration before gradually resorbing and leaving native tissue behind. Clinical experience with 45+ patients and up to 6 years follow-up, with 83% volume retention at 2 years in the BRV-004 trial.
• Chest Wall/Pectus Scaffold Custom-designed bioresorbable scaffolds for chest wall reconstruction and pectus excavatum correction procedures. Engineered in collaboration with surgeons for anatomical fit while guiding tissue integration. Market access granted in Europe for custom-made pectus excavatum scaffolds.
• Bone Regeneration Scaffold Resorbable scaffolds designed to stabilize and retain bone graft material in large or complex defects, supporting structured healing and bone regeneration. European market access granted for custom-made bone scaffolds.
• Other Soft Tissue Scaffolds Bioresorbable scaffold applications extending beyond breast and bone to multiple soft tissue indications where structural support and guided regeneration are required.

Quantifiable outcome

• 83% volume retention at 2-year follow-up in 19-patient cohort
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Mentor Worldwide LLC (Johnson & Johnson)coreStrategic or Co-development PartnerExclusive global licensing agreement bringing together BellaSeno's technology with Mentor's clinical, regulatory, and commercial scale. This collaboration follows positive two-year human clinical data and will accelerate final clinical development of the breast scaffold platform as BellaSeno prepares for global market introduction.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Allergan Aesthetics (AbbVie): Market-leading breast aesthetics franchise (Natrelle) and parent of regenerative tissue brands; represents the dominant incumbent competitor BellaSeno must displace in breast reconstruction and augmentation.
• Sientra: Aesthetics company marketing breast implants (including the Viality tissue expander) for breast augmentation and reconstruction; competes with BellaSeno in the same surgical channel and patient indications.
• Integra LifeSciences: Diversified medical device leader with a portfolio of regenerative scaffolds, dural repair, and wound matrices; comparable technology category (collagen/regenerative matrices used in reconstructive surgery) and broader commercial reach than BellaSeno.
• Organogenesis: Regenerative medicine company marketing wound healing and soft-tissue regeneration products (e.g., Apligraf, Dermagraft) that overlap with BellaSeno's scaffold-driven soft-tissue regeneration value proposition.
• GC Aesthetics: Global breast implant and tissue-expander manufacturer serving the same plastic and reconstructive surgery channel; incumbent competitor for surgeon adoption against BellaSeno's scaffold.
• MTF Biologics (Musculoskeletal Transplant Foundation): Non-profit tissue bank providing allograft and regenerative biologic products for reconstruction, sports medicine, and wound healing; adjacent competitor in the regenerative soft-tissue/bone space.

Emerging players

• CollPlant Biotechnologies: Israel-based regenerative aesthetics company developing bio-printed regenerative breast implants using recombinant human collagen; the most technology-comparable peer to BellaSeno's bioresorbable breast scaffold thesis.
• Tissium: Polymer-based tissue repair platform combining bioresorbable materials with proprietary adhesion technology for tissue reconstruction; overlaps with BellaSeno on bioresorbable, scaffold-driven soft-tissue regeneration.

Direct peers

• Establishment Labs: Public aesthetics company that markets Motiva breast implants and is investing in regenerative/biology-based breast technologies; competes directly with BellaSeno for surgeon mindshare in breast reconstruction and augmentation.
• Polyganics: Netherlands-based medical device company developing bioresorbable polymer-based devices for soft-tissue repair and reconstruction; comparable business model (bioresorbable scaffolds for soft tissue) and similar clinical-stage profile.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/bellaseno

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bellaseno